Predix Header
Overview Management Marketplace Science & Process Product Pipeline News, Events, Info Home


redix senior management brings valuable expertise in computational biology, molecular biology, computational chemistry, drug discovery, pharmaceutical product development, and medicinal chemistry, as well as business development and financial experience within both private and public companies.


Michael Kauffman M.D., Ph.D., President and CEO
Dr. Kauffman received his M.D. and Ph.D. (molecular biology and biochemistry) at Johns Hopkins and his postdoctoral training at Harvard University. He is board certified in internal medicine, and comes with over 10 years of extensive experience in drug discovery and development.

Dr. Kauffman joined Predix after being the Vice President, Medicine, and Proteasome Inhibitor (VELCADE™) Program Leader at Millennium Pharmaceuticals Inc. Prior to that, Dr. Kauffman held senior positions at Millennium Predictive Medicine, Inc., as cofounder and Vice President of Medicine, and at Biogen Corporation.

(781) 376-0811 x1013


Silvia Noiman, Ph.D., MBA
Founder & Sr. VP of Pipeline Management
General Manager, Israel
Dr. Noiman received a B.Sc in Biology, M.Sc. (Summa Cum Laude) in Genetics, and a Ph.D. in Molecular Biology from Tel Aviv University. Dr. Noiman held an academic position at the Weizmann Institute of Science.

Before founding Predix Dr. Noiman founded and managed a genetic diagnostic unit at the Tel-Hashomer Hospital in Israel, she held scientific advisory positions at the Ministry of Science and coordinated the activities of the Israeli National Biotechnology Committee. Dr. Noiman has published numerous scientific papers.

+972-3-612-8590 x101


Chen Schor, MBA, CPA, Chief Business Officer
Mr. Schor comes with over 10 years of experience in the healthcare, financial and venture capital fields. Prior to joining Predix, Mr. Schor served as Partner, Life Sciences, and Chief Financial Officer, at Yozma Venture Capital Group, managing a fund of more than $220 MM. Mr. Schor was one of the lead investors in Predix Pharmaceuticals Ltd. when the company incorporated in 2000. Mr. Schor previously held positions at Arthur Anderson and BDO consultants and holds an MBA, BA in biology, BA in economics and is a Certified Public Accountant (CPA).

(781) 376-0821 x1028


Oren Becker, Ph.D., Co-Founder and CSO, Computational Development
Dr. Becker is a computational biophysicist with over 17 years of experience. Dr. Becker received his B.Sc in Physics and Chemistry summa cum laude, a B.A in Philosophy magna cum laude and a Ph.D. in Theoretical Chemical Physics from the Hebrew University of Jerusalem.

Before founding Predix Dr. Becker held a position as a visiting professor at Harvard University and a professor at Tel Aviv University.

Dr. Becker has published numerous scientific papers and has co-edited a highly praised Textbook for the field of computational biochemistry and biophysics (published 2001).

+972-3-612-8590 x101


Dale S. Dhanoa, Ph.D., SVP of Research & Discovery
Dr. Dhanoa is a medicinal chemist with over 15 years of extensive experience in drug discovery of GPCR targets.

Dr. Dhanoa has joined Predix after being the CSO at Pharmacore, Inc. Prior to that Dr. Dhanoa held senior positions at Merck Research Laboratories, 3-Dimensional Pharmaceuticals, Synaptic Pharmaceutical and Alanex/Agouron.

(781) 376-0821 x1012


Christine H. Wang, Vice President, Drug Development Operations
Ms. Wang brings an extensive background in drug development with 15 years of experience in areas spanning Quality Assurance (GMP, GLP & GCP), Manufacturing, Clinical Operations, and Program Management.

Prior to joining Predix, she held key positions on programs at Genetics Institute (Wyeth) and most recently at Millennium Pharmaceuticals, where she was the Program Manager of the Proteasome Inhibitor (VELCADETM) Program. .

(781) 376-0821 x1014